- Home
- SSSS vs OBIO Comparison
SSSS vs OBIO Comparison
Compare SSSS & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSSS
- OBIO
- Stock Information
- Founded
- SSSS 2010
- OBIO 2017
- Country
- SSSS United States
- OBIO United States
- Employees
- SSSS N/A
- OBIO N/A
- Industry
- SSSS Finance: Consumer Services
- OBIO Medicinal Chemicals and Botanical Products
- Sector
- SSSS Finance
- OBIO Health Care
- Exchange
- SSSS Nasdaq
- OBIO Nasdaq
- Market Cap
- SSSS 138.2M
- OBIO 146.2M
- IPO Year
- SSSS N/A
- OBIO N/A
- Fundamental
- Price
- SSSS $9.98
- OBIO $2.83
- Analyst Decision
- SSSS Strong Buy
- OBIO Strong Buy
- Analyst Count
- SSSS 4
- OBIO 4
- Target Price
- SSSS $9.50
- OBIO $14.00
- AVG Volume (30 Days)
- SSSS 186.1K
- OBIO 227.6K
- Earning Date
- SSSS 11-06-2025
- OBIO 11-11-2025
- Dividend Yield
- SSSS 10.67%
- OBIO N/A
- EPS Growth
- SSSS N/A
- OBIO N/A
- EPS
- SSSS 2.22
- OBIO N/A
- Revenue
- SSSS $2,784,381.00
- OBIO $2,944,000.00
- Revenue This Year
- SSSS $7,183.09
- OBIO $29.26
- Revenue Next Year
- SSSS N/A
- OBIO $10.65
- P/E Ratio
- SSSS $4.22
- OBIO N/A
- Revenue Growth
- SSSS N/A
- OBIO 41.61
- 52 Week Low
- SSSS $3.87
- OBIO $2.20
- 52 Week High
- SSSS $9.50
- OBIO $6.50
- Technical
- Relative Strength Index (RSI)
- SSSS 74.65
- OBIO 62.77
- Support Level
- SSSS $8.75
- OBIO $2.20
- Resistance Level
- SSSS $9.40
- OBIO $2.89
- Average True Range (ATR)
- SSSS 0.25
- OBIO 0.14
- MACD
- SSSS 0.05
- OBIO 0.04
- Stochastic Oscillator
- SSSS 99.05
- OBIO 87.00
About SSSS SuRo Capital Corp.
SuRo Capital Corp is a non-diversified closed-end management investment company. The company's investment objective is to maximize its portfolio's total return, principally by seeking capital gains on its equity and equity-related investments.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.